arrow
A

Alejandra Bruna

University of Cambridge
H指数:41
被引数:8,982

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cells

利用肿瘤异种移植来源细胞进行高通量药物筛选的实时细胞活力监测

2026-05-270
OAAI
Genetic interactions, synthetic lethality and complexity in cancer vulnerability mapping-Insights and perspectives from the 2nd EuroDepMap symposium

癌症易感性图谱中的遗传相互作用、合成致死性与复杂性——第二届EuroDepMap研讨会的见解与展望

2026-02-010
PRE
Fitness and transcriptional plasticity of human breast cancer single-cell-derived clones

人类乳腺癌单细胞来源克隆的适应性及转录组可塑性

2025-05-010
OA
Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer
2023-11-0912
OAAI
RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer

RANK是ER阴性绝经后乳腺癌的不良预后标志物和治疗靶点

2023-03-073
OAAI
MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer

MiR-182-3p靶向TRF2并损害三阴性乳腺癌的肿瘤生长

2022-11-2519
OAAI
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (September, 10.1038/s41467-022-32828-6, 2022)

高p16表达和杂合RB1丢失是ER乳腺癌中CDK4/6抑制剂抗性的生物标志物 (9月,10.1038/s41467-022-32828-6,2022)

2022-11-140
OAAI
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

高p16表达和杂合RB1缺失是ER乳腺癌中CDK4/6抑制剂耐药的生物标志物

2022-09-0747
OAAI
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

确定对WEE1或ATR抑制有反应的乳腺癌和卵巢癌模型的分子定义子集,克服PARP抑制剂耐药性

2022-08-0327
OAAI
DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation

1538乳腺癌的DNA甲基化景观揭示了与复制相关的时钟,表观基因组不稳定性和顺式调节

2021-09-1332
OAAI
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response

乳腺癌异种移植细胞表型多样性及其对药物反应的影响

2021-03-3137
OAAI
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

PI3K激活促进HER2-negative乳腺癌对eribulin的耐药性

2021-03-1513
OAAI
The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts
2020-08-150
PRE